Applications
Email Page Print Page

UGT1A1

The InvaderŪ UGT1A1 Molecular Assay is the first in vitro diagnostic pharmacogenetic test using the Invader Chemistry. The test determines the UGT1A1 *28 genotype as recommended in the label for the chemotherapeutic drug irinotecan, which is approved as a first-line therapy for metastatic colorectal cancer1. Patients with a heterozygous-deficient *1 / *28 genotype or homozygous-deficient *28 / *28 genotype have greater risk for severe toxicity when treated with irinotecan therapy.2,3

Labs running the Invader UGT1A1 Molecular Assay enjoy the following benefits4:

  • 100% accurate as compared to bi-directional sequencing of 285 clinical samples.4
  • 98% reproducibility in a multi-center clinical study.4
  • Minimal Hands-On Time (<2 hours, including DNA isolation).

For more information about the Invader UGT1A1 Molecular Assay, please click here to contact us.

  1. https://www.pfizeroncology.com/sites/pop/pages/camptosar.aspx
  2. Innocenti, F., et al. (2004). Genetic variants in the UDP-glucuronasyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 22(8), 1382-1388.
  3. Beutler, E., et al. (1998). Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci. 95, 8170-8174.
  4. The InvaderŪ UGT1A1 molecular assay package insert, p/n 15-2655
Share Page
Invader Chemistry Applications
Share Page